OBJECTIVE: Treatment delays may result in different clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) who receive fibrinolytic therapy vs primary percutaneous coronary intervention (PCI). The aim of this analysis was to examine how treatment delays relate to 6-month mortality in reperfusion-treated patients enrolled in the Global Registry of Acute Coronary Events (GRACE). DESIGN: Prospective, observational cohort study. SETTING: 106 hospitals in 14 countries. PATIENTS: 3959 patients who presented with STEMI within 6 h of symptom onset and received reperfusion with either a fibrin-specific fibrinolytic drug or primary PCI. MAIN OUTCOME MEASURES: 6-month mortality. METHODS: Multivariable logistic regression was used to assess the relationship between outcomes and treatment delay separately in each cohort, with time modelled with a quadratic term after adjusting for covariates from the GRACE risk score. RESULTS: A total of 1786 (45.1%) patients received fibrinolytic therapy, and 2173 (54.9%) underwent primary PCI. After multivariable adjustment, longer treatment delays were associated with a higher 6-month mortality in both fibrinolytic therapy and primary PCI patients (p<0.001 for both cohorts). For patients who received fibrinolytic therapy, 6-month mortality increased by 0.30% per 10-min delay in door-to-needle time between 30 and 60 min compared with 0.18% per 10-min delay in door-to-balloon time between 90 and 150 min for patients undergoing primary PCI. CONCLUSIONS: Treatment delays in reperfusion therapy are associated with higher 6-month mortality, but this relationship may be even more critical in patients receiving fibrinolytic therapy.
OBJECTIVE: Treatment delays may result in different clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) who receive fibrinolytic therapy vs primary percutaneous coronary intervention (PCI). The aim of this analysis was to examine how treatment delays relate to 6-month mortality in reperfusion-treated patients enrolled in the Global Registry of Acute Coronary Events (GRACE). DESIGN: Prospective, observational cohort study. SETTING: 106 hospitals in 14 countries. PATIENTS: 3959 patients who presented with STEMI within 6 h of symptom onset and received reperfusion with either a fibrin-specific fibrinolytic drug or primary PCI. MAIN OUTCOME MEASURES: 6-month mortality. METHODS: Multivariable logistic regression was used to assess the relationship between outcomes and treatment delay separately in each cohort, with time modelled with a quadratic term after adjusting for covariates from the GRACE risk score. RESULTS: A total of 1786 (45.1%) patients received fibrinolytic therapy, and 2173 (54.9%) underwent primary PCI. After multivariable adjustment, longer treatment delays were associated with a higher 6-month mortality in both fibrinolytic therapy and primary PCI patients (p<0.001 for both cohorts). For patients who received fibrinolytic therapy, 6-month mortality increased by 0.30% per 10-min delay in door-to-needle time between 30 and 60 min compared with 0.18% per 10-min delay in door-to-balloon time between 90 and 150 min for patients undergoing primary PCI. CONCLUSIONS: Treatment delays in reperfusion therapy are associated with higher 6-month mortality, but this relationship may be even more critical in patients receiving fibrinolytic therapy.
Authors: Kim A Eagle; Shaun G Goodman; Alvaro Avezum; Andrzej Budaj; Cynthia M Sullivan; José López-Sendón Journal: Lancet Date: 2002-02-02 Impact factor: 79.321
Authors: C P Cannon; C M Gibson; C T Lambrew; D A Shoultz; D Levy; W J French; J M Gore; W D Weaver; W J Rogers; A J Tiefenbrunn Journal: JAMA Date: 2000-06-14 Impact factor: 56.272
Authors: Duane S Pinto; Ajay J Kirtane; Brahmajee K Nallamothu; Sabina A Murphy; David J Cohen; Roger J Laham; Donald E Cutlip; Eric R Bates; Paul D Frederick; Dave P Miller; Joseph P Carrozza; Elliott M Antman; Christopher P Cannon; C Michael Gibson Journal: Circulation Date: 2006-10-30 Impact factor: 29.690
Authors: Kim A Eagle; Michael J Lim; Omar H Dabbous; Karen S Pieper; Robert J Goldberg; Frans Van de Werf; Shaun G Goodman; Christopher B Granger; P Gabriel Steg; Joel M Gore; Andrzej Budaj; Alvaro Avezum; Marcus D Flather; Keith A A Fox Journal: JAMA Date: 2004-06-09 Impact factor: 56.272
Authors: Albert Schömig; Gjin Ndrepepa; Julinda Mehilli; Markus Schwaiger; Helmut Schühlen; Stephan Nekolla; Jürgen Pache; Stefan Martinoff; Hildegard Bollwein; Adnan Kastrati Journal: Circulation Date: 2003-08-18 Impact factor: 29.690
Authors: Christopher B Granger; Robert J Goldberg; Omar Dabbous; Karen S Pieper; Kim A Eagle; Christopher P Cannon; Frans Van De Werf; Alvaro Avezum; Shaun G Goodman; Marcus D Flather; Keith A A Fox Journal: Arch Intern Med Date: 2003-10-27
Authors: Jakob Dörler; Hannes Franz Alber; Johann Altenberger; Gerhard Bonner; Werner Benzer; Georg Grimm; Kurt Huber; Lalit Kaltenbach; Karl-Peter Pfeiffer; Herwig Schuchlenz; Peter Siostrzonek; Gerald Zenker; Otmar Pachinger; Franz Weidinger Journal: Wien Klin Wochenschr Date: 2010-04 Impact factor: 1.704
Authors: Felix Post; Evangelos Giannitsis; Thomas Riemer; Lars S Maier; Claus Schmitt; Burghard Schumacher; Gerd Heusch; Harald Mudra; Thomas Voigtländer; Rainer Erbel; Harald Darius; Hugo Katus; Christian Hamm; Jochen Senges; Tommaso Gori; Thomas Münzel Journal: Clin Res Cardiol Date: 2012-07-25 Impact factor: 5.460